This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Added on the pullback this morning. Looks like more news on the way and this one as a very high beta which should send the price higher.

cheers GF

What do you mean by high beta?
What news?

Medical Marketing Int'l Group PLC
02 February 2005


MEDICAL MARKETING INTERNATIONAL GROUP PLC ('MMI')

HOLDING IN COMPANY

The Company received notification on the 1 February 2005, from M&G Investment
Management Limited that Prudential plc and certain of its subsidiary companies
are interested in 7,314,000 0.2p ordinary shares in the Company, representing
14.39 per cent of the Company's current ordinary issued share capital. The
registered holders of these shares are Nortrust Nominee Ltd (5,074,717 shares),
Nortrust Noms Ltd (1,731,923 shares), and Pruclt HSBC Gis Nom (UK) PPL
(507,360 shares).

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange

Pete, a high beta leads to good news pushing the share price up higher than the norm in % terms, a low beta the other way round. Eg, take a look at this ones chart and notice the volatility in the chart then take a look at Deal Group Medias price chart which as a low beta you will see that the volatility is well less pronounced. You can find a more detailed explanation on Yahoo finance.

News flow is expected any time according to followers of the Mike Walters site and there should be plenty of it.

cheers GF.

Ok just read up and high beta means in a bull phase, high betas will outperform the average whilst in a bear phase, they will underperform so implies a stock on the extremes. Can't see how that relates to good news or pushing the price higher unless the general market continues to move higher.

I have researched some of the pharma sector but cannot understand the excitement.
The Genvax drug in Phase II is up against at least 100 other drugs targeting the same cancer also in Phase II and Phase III.
Can't see why Genvax has any more chance than the other 100 drugs listed in trials.

As for the Ruthenium, The drug is behind schedule for Phase II start and has not been granted approval by the FDA to start (Why?).
There are currently over 1000 treatments in Phase II and Phase III trials for the proposed Ruthenium target cancers so competition is stiff.
You do not start Phase II or Phase III if you don't think you are going to make money so the 1000 rivals must all think they have good products.

Viratis is a long way off the clinic and I have not researched the number of HIV drugs currently in Phase II or Phase III so cannot comment but I would imagine competition is fierce.

My point being that in the GENVAX example, only a small fraction of the 100 drugs in trials will reach the market with varying degrees of success.
Until the trial data is studied and a pharma is interested, it is worth not much at all. Infact I think MMG value it in their accounts at 1 as they do Oncosence etc.

Correct Oncosense and Genvax are both valued at 100p in the latest accounts as they have no value whatsoever on the Balance sheet and until a larger pharma bids for them they will continue to be worth just 100p each..this is standard accounting policy.

So a quick asset valuation is the products as they stand are worth 3 against a Mkt Cap of the company at 45 Million.
Hence my caution.

In a nutshell that is correct..300p on the balance sheet against a market cap of 42m.

I was under the impression that the general market was moving higher the indicies show that. Anyway Im sticking with them as I think we have a real winner here.

Lovely chart forming.



cheers GF.

Added a few more, not many but a buys a buy.

cheers GF.

Its gone positive now. NICE.

cheers GF.

Good luck GF I'm still holding for the next 12 months anyhow....

Anyhow?, what do you mean Mitzy these are the hottest property around.

Give it some hype mate.

cheers GF.

You are right there GF... seen the RNS...?

Yup and heres Killik Brokers backing it.....................

And heres some of that news flow from Killik Broker morning notes...................

Medical Marketing, the UK based pharmaceutical firm, announces that it has reached agreement with its joint venture partner, Kings College London, to licence a novel hepatitis therapy. The platform technology Viratis has already demonstrated that it can prevent HIV from penetrating human cells by a process of education. The news today is that they believe it works just as well in treating Hepatitis B, a market some magnitude larger. Medical Marketing will be funding the research to the tune of around 400,000 in return for which it will increase its stake in Viratis to 72%. The stock continues its rise to 90p in early trade and whilst this announcement is some way ahead of anything hitting the clinical lab, it serves to demonstrate the value in its portfolio and relationships with the Universitiesends BUY, BUY, BUY.

cheers GF.

Wow just look at it go, up 14%, NICE.

cheers Gf

Superb chart.



cheers GF.

My previous target was for 400p year end but I am erring on the side of caution as the sp has increased too fast in the last month and therefore I am reducing the target to 120p to 200p.
Longer term I see no problem with 400p to 500p.I recall IC stating that they were a possible 10 bagger at 60p;talk of 1000p and 1500p a share is fantasy.

two quid plus will do me.

cheers GF.